- Home
- KOD vs ANAB Comparison
KOD vs ANAB Comparison
Compare KOD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | ANAB |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KOD | ANAB |
|---|---|---|
| Price | $23.70 | $62.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $28.29 | ★ $68.10 |
| AVG Volume (30 Days) | ★ 510.9K | 477.1K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.60 | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $1.92 | $15.32 |
| 52 Week High | $31.18 | $66.66 |
Technical Indicators
Market Signals| Indicator | KOD | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 64.94 |
| Support Level | $21.19 | $43.67 |
| Resistance Level | $26.21 | N/A |
| Average True Range (ATR) | 1.71 | 3.68 |
| MACD | -0.27 | 0.69 |
| Stochastic Oscillator | 14.96 | 77.18 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).